Leap Therapeutics Inc

LPTX

Company Profile

  • Business description

    Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

  • Contact

    47 Thorndike Street
    Suite B1-1
    CambridgeMA02141
    USA

    T: +1 617 714-0360

    E: [email protected]

    https://www.leaptx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    52

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.7048.800.56%
CAC 407,902.2523.790.30%
DAX 4024,456.8192.75-0.38%
Dow JONES (US)44,650.64192.340.43%
FTSE 1008,975.66108.641.23%
HKSE24,028.37136.050.57%
NASDAQ20,630.6619.330.09%
Nikkei 22539,646.36174.92-0.44%
NZX 50 Index12,800.2240.020.31%
S&P 5006,280.4617.200.27%
S&P/ASX 2008,589.2050.600.59%
SSE Composite Index3,509.6816.630.48%

Market Movers